Emerging roles of sodium‐glucose co‐transporter inhibitors

Abstract

Originally introduced as antidiabetic agents, the use of sodium‐glucose co‐transporter protein (SGLT) inhibitors has now expanded to a wider range of indications, including heart failure and chronic kidney disease, following positive clinical trial outcomes. This article summarises the properties of SGLT inhibitors and the increasing evidence base for their use in many cardiovascular and renal conditions.